Wire · operational-macro
FDA approves surgery-sparing immunotherapy for rectal cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 20 October 2026 · Fusion42 review
The FDA has granted accelerated approval to GSK's dostarlimab-gxly (Jemperli) as a standalone immunotherapy for adults with previously untreated stage 2 or 3 locally advanced rectal cancer, identified by specific genetic markers. This treatment may allow eligible patients to avoid chemotherapy, radiation, and surgery based on trial results showing a high rate of avoiding these interventions.
This Wire brief sits within Fusion42's coverage of Biotech, and 15 sources have reported it between 19 Oct 2026 and 25 Oct 2026.
◆ ◆ The Wire takeaway
You need to reposition your oncology offerings around immunotherapies like Jemperli now approved for rectal cancer, as surgery and chemo could become optional rather than mandatory. This approval opens a market gap for diagnostics firms focusing on genetic tumour profiling to partner or compete.
◆ Coverage
15 sources · first reported 19 Oct 2026 · latest 25 Oct 2026
◆ Related on Wire
◆ Topics